Shots: AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas The companies will continue to explore overseas business collaborations including emerging […]Read More
Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout Published: Oct 1, 2020 | Tags: Chronic Refractory Gout, COMPARE Study, Important Clinical Improvement, P-II, patients, reports, results, SEL-212, Selecta Biosciences, Sobi 2. Moderna’s mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults Published: Oct 1, 2020 | Tags: COVID-19, […]Read More
1. AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC Published: Sept 18, 2020 | Tags: AstraZeneca, Reports, Updated Results, Imfinzi, P-III, Studies, NSCLC, ES-SCLC 2. Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia Published: Sept 18, 2020 | Tags: Roche, Actemra, EMPACTA study, […]Read More
Shots: Wigen to transfer its 50% interest in four drugs WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 to Junshi. Wigen to receive $5.3M up front, $64.3M as milestones, and 50% on the net profit of the therapies Junshi to get WW exclusive rights for the production and commercialization of these drugs and will be responsible for clinical […]Read More
Shots: The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while Impact will supply senaparib in Mainland China, Hong Kong, and Macau representing the other 50% The JV will focus on the research, development & commercialization […]Read More
Shots: The companies plan to file IND submission and initiate human clinical studies to evaluate neutralizing mAbs against COVID-19 in the US and China in Q2’2020 The article is being published in Nature, reports the identification and characterization of two mAb’s CA1 and CB6 from the COVID-19 recovered patients CA1 and CB6 mAb’s have demonstrated […]Read More
Shots: Lilly will get an exclusive license to perform clinical development, manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
